SCHEMBL10243051

SCHEMBL10243051

C=C(Nc1ccc(Oc2ccnc3cc(OCC4CCNCC4)c(OC)cc23)c(F)c1)C(=O)NCCc1ccc(OCC)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.58
FLT3 P36888 5/20 0.52
KDR P35968 2/20 0.48
AXL P30530 2/20 0.48
EGFR P00533 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371869 0.94 MET (0.60) METFLT3KDRAXL
SCHEMBL371763 0.93 MET (0.60) METFLT3KDRAXLEGFR
SCHEMBL371555 0.90 MET (0.63) METFLT3KDRAXL
SCHEMBL14379860 0.89 MET (0.58) METFLT3KDRAXL
SCHEMBL372239 0.88 MET (0.61) METFLT3KDRAXL
SCHEMBL20525875 0.88 MET (0.61) METFLT3KDRAXL
SCHEMBL374695 0.88 MET (0.60) METFLT3KDRAXL
SCHEMBL371865 0.88 MET (0.61) METFLT3KDRAXL
SCHEMBL407778 0.87 MET (0.62) METFLT3KDRAXL
SCHEMBL372669 0.87 MET (0.62) METFLT3KDRAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 EP disclosed
EP-2392565-A1 c-Met modulators and methods of use Exelixis Inc. (US) 2011-12-07 EP disclosed
EP-2392564-A1 c-Met modulators and methods of use Exelixis Inc. (US) 2011-12-07 EP disclosed
EP-2213661-A1 c-Met Modulators and Methods of Use Exelixis Inc. (US) 2010-08-04 EP disclosed
EP-2210607-A1 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer Exelixis Inc. (US) 2010-07-28 EP disclosed